MCID: GLC008
MIFTS: 52

Glucose Metabolism Disease

Categories: Metabolic diseases

Aliases & Classifications for Glucose Metabolism Disease

MalaCards integrated aliases for Glucose Metabolism Disease:

Name: Glucose Metabolism Disease 12 15
Glucose Metabolism Disorders 44 73
Disorder of Glucose Metabolism 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4194
MeSH 44 D044882
NCIt 50 C53655
SNOMED-CT 68 126877002
UMLS 73 C1257958

Summaries for Glucose Metabolism Disease

MalaCards based summary : Glucose Metabolism Disease, also known as glucose metabolism disorders, is related to diabetes mellitus and prader-willi syndrome. An important gene associated with Glucose Metabolism Disease is PINK1-AS (PINK1 Antisense RNA
As the name suggests,PINK1 is induced by PTEN,which is an important inhibitor of insulin signalling. PINK1 depletion has been associated with diabetes status,impaired glucose uptake in neuronal cell lineand with mitochondrial gene expression in adipocytes ,raising the possibility that disruption to naPINK1 may impact on glucose metabolism.
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Metabolism of proteins and Developmental Biology. The drugs Zinc and Metformin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Glucose Metabolism Disease

Diseases related to Glucose Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus 31.3 ACE ADIPOQ ALB CRP DPP4 GCG
2 prader-willi syndrome 31.0 ADIPOQ IGF1 INS LEP
3 coronary artery anomaly 30.9 ACE ADIPOQ CRP INS IRS1
4 diabetes mellitus, noninsulin-dependent 29.7 ACE ADIPOQ ALB CRP DPP4 GCG
5 malignant otitis externa 11.3 CRP INS
6 nonalcoholic steatohepatitis 11.2 ADIPOQ INS LEP
7 acquired generalized lipodystrophy 11.2 ADIPOQ LEP
8 mixed cell adenoma 11.2 IGF1 IRS1
9 ischemic heart disease 11.2 ACE CRP INS
10 hyporeninemic hypoaldosteronism 11.2 ACE REN
11 fetal macrosomia 11.2 IGF1 INS LEP
12 orthostatic proteinuria 11.2 ACE ALB REN
13 familial partial lipodystrophy 11.2 INS LEP PPARG
14 acute insulin response 11.2 CRP GCG INS
15 anuria 11.2 ACE ALB REN
16 nutritional deficiency disease 11.2 ALB CRP LEP
17 intermittent claudication 11.2 ACE ALB CRP
18 protein-energy malnutrition 11.2 ALB IGF1 LEP
19 type 1 diabetes mellitus 15 11.2 GCG INS
20 renal hypertension 11.2 ACE ALB REN
21 hepatorenal syndrome 11.2 ACE ALB REN
22 pyelonephritis 11.2 ACE ALB CRP
23 acute cystitis 11.2 ALB CRP IER3IP1
24 peripheral nervous system disease 11.2 INS PSMD9 TRPV1
25 dysentery 11.2 ALB CRP IER3IP1
26 severe pre-eclampsia 11.2 ADIPOQ ALB LEP
27 inherited metabolic disorder 11.2 ADIPOQ CRP INS LEP
28 idiopathic edema 11.1 ACE ADIPOQ INS PPARG
29 anovulation 11.1 IGF1 INS LEP
30 3-hydroxyacyl-coa dehydrogenase deficiency 11.1 ADIPOQ INS LEP PPARG
31 coronary stenosis 11.1 ACE ALB CRP
32 uremia 11.1 ALB CRP INS LEP
33 abdominal obesity-metabolic syndrome quantitative trait locus 2 11.1 CRP INS LEP SLC2A4
34 coronary heart disease 1 11.1 ACE ADIPOQ CRP INS
35 retinal vascular disease 11.1 ALB IGF1 INS PSMD9
36 renal artery obstruction 11.1 ACE REN
37 secondary adrenal insufficiency 11.1 IGF1 INS
38 bladder disease 11.1 CRP IER3IP1 TRPV1
39 immune system disease 11.1 ACE ALB CRP TRPV1
40 severe nonproliferative diabetic retinopathy 11.1 ALB INS
41 obesity-hypoventilation syndrome 11.1 ADIPOQ LEP
42 microvascular complications of diabetes 5 11.1 ACE ALB IGF1 INS
43 mental depression 11.1 DPP4 IER3IP1 PSMD9
44 atherosclerosis susceptibility 11.1 ADIPOQ CRP INS PPARG
45 microvascular complications of diabetes 3 11.1 ACE ALB INS REN
46 hypersensitivity reaction disease 11.1 ACE ALB TRPV1
47 autoinflammation, lipodystrophy, and dermatosis syndrome 11.1 ADIPOQ CRP PPARG
48 hypertensive retinopathy 11.1 ACE ADIPOQ PSMD9 REN
49 benign essential hypertension 11.1 ALB REN
50 generalized atherosclerosis 11.1 ACE CRP

Graphical network of the top 20 diseases related to Glucose Metabolism Disease:



Diseases related to Glucose Metabolism Disease

Symptoms & Phenotypes for Glucose Metabolism Disease

MGI Mouse Phenotypes related to Glucose Metabolism Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 BACE1 CRP ACE DPP4 IAPP IGF1
2 growth/size/body region MP:0005378 10.25 BACE1 ACE DPP4 IAPP IGF1 ADIPOQ
3 cardiovascular system MP:0005385 10.2 INS CRP ACE IGF1 ADIPOQ TRPV1
4 adipose tissue MP:0005375 10.18 IRS1 ACE IGF1 ADIPOQ INS SLC2A4
5 endocrine/exocrine gland MP:0005379 10.13 ALB INS DPP4 ACE IGF1 ADIPOQ
6 immune system MP:0005387 10.13 INS CRP ACE IAPP IGF1 ADIPOQ
7 liver/biliary system MP:0005370 9.91 INS ACE ADIPOQ ALB PPARG IRS1
8 muscle MP:0005369 9.85 BACE1 IGF1 ADIPOQ INS ALB REN
9 neoplasm MP:0002006 9.5 ALB ACE IGF1 ADIPOQ TRPV1 PPARG
10 renal/urinary system MP:0005367 9.32 ACE IGF1 ADIPOQ INS ALB REN

Drugs & Therapeutics for Glucose Metabolism Disease

Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1087)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 23994
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
5
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
6
Ticlopidine Approved Phase 4 55142-85-3 5472
7
Ezetimibe Approved Phase 4,Phase 3,Phase 2 163222-33-1 150311
8
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10238-21-8 3488
9
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 56180-94-0 441184
10
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 361442-04-8 11243969
11
Gliclazide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21187-98-4 3475
12
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
13
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 133107-64-9
14
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
15
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 204656-20-2 44147092
16
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 116094-23-6 16132418
17
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 850649-61-5 11450633
18
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93479-97-1 3476
19
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 111025-46-8 4829
20
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169148-63-4 5311023
21
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 207748-29-6
22
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274901-16-5 6918537
23
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 29094-61-9 3478
24
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 668270-12-0 10096344
25
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 159351-69-6 6442177
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
27
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53123-88-9 5284616 6436030 46835353
28
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
29
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
30
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 137862-53-4 60846
32
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
33
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
34
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
35
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
36
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Not Applicable 10102-43-9 145068 160954
37
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 75847-73-3 5362032 40466924
38
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Not Applicable 76420-72-9 6917719
39
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135062-02-1 65981
40
Nateglinide Approved, Investigational Phase 4,Phase 3,Phase 2 105816-04-4 60026
41
AT-101 Approved, Investigational Phase 4,Not Applicable 90141-22-3, 652-67-5 12597
42
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
43
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 1 128-13-2 31401
44
Canagliflozin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 842133-18-0
45
Oxymetazoline Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 1491-59-4 4636
46
Phenylephrine Approved Phase 4,Phase 2,Phase 1,Not Applicable 59-42-7 6041
47
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
48
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
49
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
50
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0

Interventional clinical trials:

(show top 50) (show all 10001)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effects of Insulin and Berberine on Stress Hyperglycemia Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
2 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
3 Lactate and Hypoglycemia Unknown status NCT01387477 Phase 4 Lactate;Glucose
4 Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus Unknown status NCT02775253 Phase 4
5 Glucometer and Mobile-phone Based Data Transfer System in Diabetes Unknown status NCT02769377 Phase 4
6 Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
7 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
8 Randomized Trial Comparing Colesevelam vs. Ezetimibe Unknown status NCT02682680 Phase 4 Colesevelam;Ezetimibe
9 Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) Unknown status NCT02624830 Phase 4 Sulfonylurea
10 A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes Unknown status NCT02606617 Phase 4 Mosapride;Placebo
11 Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin
12 Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes Unknown status NCT02526810 Phase 4 insulin lispro;Insulin Glargine
13 Syringes Replacement for Insulin Application for Pens Device in a Population of Elderly Patients With Type 2 Diabetes: Multifactorial Intervention to Improve Glycemic Control Unknown status NCT02517242 Phase 4
14 Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
15 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
16 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
17 Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes Unknown status NCT02449603 Phase 4 Exenatide;Biphasic insulin Aspart 30
18 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
19 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
20 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
21 Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes Unknown status NCT02344186 Phase 4 Liraglutide
22 Comparative Study of Antibacterial Effect on Silver Dressing of Negative Pressure Wound Unknown status NCT02274207 Phase 4
23 The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
24 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
25 Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients Unknown status NCT02219750 Phase 4 switch twice-daily insulin
26 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
27 Triple Therapy in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4 Metformin;Pioglitazone;Sitagliptin
28 TReatment by Insulin Continuous Infusion in Type 2 DIAbetes Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
29 Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes Unknown status NCT01867502 Phase 4 MET + Vildagliptin Group;MET + Glibenclamide Group
30 Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function Unknown status NCT01790308 Phase 4 CSII;Liraglutide
31 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
32 Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Unknown status NCT01565096 Phase 4 Metformin;Metformin;Vildagliptin;Glimepiride
33 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
34 The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients Unknown status NCT01510509 Phase 4
35 Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use Unknown status NCT01500850 Phase 4 nph insulin;human insulin;Insulin Glargine;Insulin glulisine
36 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4 Exenatide
37 Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study Unknown status NCT01417897 Phase 4 Insulin glulisine;Insulin aspart;Regular human insulin
38 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
39 Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes Unknown status NCT01339143 Phase 4 Galvus (vildagliptin);pioglitazone
40 Organization Program of DiabEtes INsulIN ManaGement Unknown status NCT01338376 Phase 4 Scilin®M30
41 Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes Unknown status NCT01281605 Phase 4
42 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
43 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
44 Korean AMADEUS Study Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
45 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
46 Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4 simvastatin/ezetimibe;atorvastatin 20mg
47 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
48 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
49 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
50 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin

Search NIH Clinical Center for Glucose Metabolism Disease

Cochrane evidence based reviews: glucose metabolism disorders

Genetic Tests for Glucose Metabolism Disease

Anatomical Context for Glucose Metabolism Disease

MalaCards organs/tissues related to Glucose Metabolism Disease:

41
Endothelial, Heart, Kidney, Testes, Liver, Pancreas, Bone

Publications for Glucose Metabolism Disease

Articles related to Glucose Metabolism Disease:

(show all 15)
# Title Authors Year
1
Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using (18)F-FDG-PET. ( 27763550 )
2016
2
Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. ( 24704332 )
2014
3
Relation of Periodontitis and Metabolic Syndrome with Gestational Glucose Metabolism Disorder. ( 23952077 )
2013
4
The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. ( 22345342 )
2012
5
Prevalence of diabetes mellitus and glucose metabolism disorders in the first degree relatives of type 2 diabetic patients. ( 22693973 )
2012
6
Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders. ( 22291689 )
2011
7
Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. ( 19909503 )
2009
8
[Association of the calpain-10 gene polymorphism with glucose metabolism disorder in pregnant women]. ( 19570442 )
2009
9
Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. ( 20098572 )
2009
10
[The dual (joker) function of glucose: study of its association with aging and glucose metabolism disorders]. ( 18942362 )
2008
11
Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. ( 18240540 )
2007
12
[Glucose metabolic disorders in relation with insulin resistance in pediatric age]. ( 15799852 )
2005
13
[Relationship between glucose metabolic disorders and expression of insulin receptor in posthepatitic cirrhosis hepatocyte and HBV DNA in pancreatic cells]. ( 15340556 )
2003
14
[Role of the steroids, SHBG, IGF-1, IGF BP-3 and growth hormone in glucose metabolism disorders during long-term treatment with low doses of glucocorticoids]. ( 11925670 )
2002
15
Evaluation of glucose metabolic disorder: insulin resistance and insulin receptors in critically ill children. ( 9275360 )
1996

Variations for Glucose Metabolism Disease

Expression for Glucose Metabolism Disease

Search GEO for disease gene expression data for Glucose Metabolism Disease.

Pathways for Glucose Metabolism Disease

Pathways related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 ACE BACE1 DPP4 GCG IAPP IGF1
2
Show member pathways
13.38 ADIPOQ IAPP INS IRS1 LEP PPARG
3 12.36 ADIPOQ GCG INS IRS1 PPARG SLC2A4
4
Show member pathways
12.22 ADIPOQ IGF1 INS IRS1 LEP PPARG
5
Show member pathways
12.06 INS IRS1 LEP SLC2A4
6
Show member pathways
11.96 ACE DPP4 GCG IGF1 INS LEP
7
Show member pathways
11.95 ADIPOQ IGF1 INS IRS1 PPARG
8
Show member pathways
11.94 IGF1 INS IRS1 SLC2A4
9
Show member pathways
11.72 ADIPOQ INS IRS1 SLC2A4
10 11.62 ADIPOQ IGF1 INS IRS1 LEP PPARG
11 11.54 ADIPOQ IRS1 LEP SLC2A4
12
Show member pathways
11.48 DPP4 GCG LEP
13 11.43 IRS1 LEP SLC2A4
14 11.39 INS IRS1 LEP
15 11.22 IGF1 INS IRS1
16 11.03 ADIPOQ LEP PPARG
17 10.79 INS SLC2A4
18
Show member pathways
10.78 IRS1 SLC2A4
19 10.36 ADIPOQ IRS1 LEP PPARG SLC2A4

GO Terms for Glucose Metabolism Disease

Cellular components related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ACE ADIPOQ ALB CRP DPP4 GCG
2 endoplasmic reticulum lumen GO:0005788 9.46 ALB BACE1 GCG INS
3 extracellular space GO:0005615 9.32 ACE ADIPOQ ALB CRP GCG IAPP

Biological processes related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.99 ADIPOQ GCG IAPP IGF1 INS LEP
2 cellular protein metabolic process GO:0044267 9.88 ALB BACE1 IAPP IGF1 INS
3 positive regulation of protein kinase B signaling GO:0051897 9.85 IAPP INS IRS1 LEP
4 positive regulation of MAPK cascade GO:0043410 9.84 IAPP IGF1 INS LEP
5 response to organic substance GO:0010033 9.83 IGF1 INS PPARG REN
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 ADIPOQ IGF1 INS
7 response to nutrient GO:0007584 9.8 ADIPOQ LEP PPARG
8 cellular response to insulin stimulus GO:0032869 9.8 ADIPOQ IRS1 PPARG SLC2A4
9 response to glucose GO:0009749 9.79 ADIPOQ IGF1 INS
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 IGF1 INS LEP
11 regulation of insulin secretion GO:0050796 9.76 DPP4 GCG LEP
12 response to insulin GO:0032868 9.76 IGF1 INS IRS1 LEP
13 glucose metabolic process GO:0006006 9.75 ADIPOQ INS LEP
14 regulation of blood pressure GO:0008217 9.73 ACE LEP PPARG REN
15 regulation of fat cell differentiation GO:0045598 9.66 LEP PPARG
16 fatty acid oxidation GO:0019395 9.65 ADIPOQ PPARG
17 insulin-like growth factor receptor signaling pathway GO:0048009 9.65 IGF1 IRS1
18 negative regulation of gluconeogenesis GO:0045721 9.64 ADIPOQ INS
19 angiotensin maturation GO:0002003 9.63 ACE REN
20 response to nutrient levels GO:0031667 9.62 ADIPOQ IGF1 INS LEP
21 positive regulation of protein kinase A signaling GO:0010739 9.61 ADIPOQ IAPP
22 negative regulation of blood vessel diameter GO:0097756 9.61 CRP INS
23 negative regulation of lipid storage GO:0010888 9.6 CRP LEP
24 positive regulation of glycogen biosynthetic process GO:0045725 9.58 IGF1 INS IRS1
25 negative regulation of acute inflammatory response GO:0002674 9.57 INS PPARG
26 bone mineralization involved in bone maturation GO:0035630 9.56 IGF1 LEP
27 amyloid-beta metabolic process GO:0050435 9.54 ACE BACE1 REN
28 positive regulation of glucose import GO:0046326 9.46 ADIPOQ IGF1 INS IRS1
29 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.43 ADIPOQ CRP PPARG
30 positive regulation of insulin receptor signaling pathway GO:0046628 9.26 IGF1 INS IRS1 LEP
31 glucose homeostasis GO:0042593 9.17 ADIPOQ IGF1 INS IRS1 LEP PPARG
32 negative regulation of apoptotic process GO:0043066 10.05 ALB GCG IGF1 INS LEP
33 positive regulation of cell proliferation GO:0008284 10.04 DPP4 IGF1 INS IRS1 LEP

Molecular functions related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.81 ADIPOQ ALB CRP DPP4 GCG IAPP
2 signaling receptor binding GO:0005102 9.8 ADIPOQ DPP4 GCG IAPP LEP REN
3 endopeptidase activity GO:0004175 9.61 ACE BACE1 REN
4 drug binding GO:0008144 9.58 ACE ALB PPARG
5 insulin receptor binding GO:0005158 9.43 IGF1 INS IRS1
6 receptor activator activity GO:0030546 9.37 IGF1 INS
7 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS IRS1 REN
8 hormone activity GO:0005179 9.1 ADIPOQ GCG IAPP IGF1 INS LEP

Sources for Glucose Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....